News and Trends 18 Apr 2016
Very promising Results for Resistant Lung Cancer
Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival. Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland). One of the hard-to-treat cancers that Ariad is targeting is […]